PET/MR in Locally Advanced Nasopharyngeal Carcinoma

Launched by ZHEJIANG CANCER HOSPITAL · Aug 31, 2018

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging technique called PET/MR to help better understand and treat a type of cancer known as nasopharyngeal carcinoma, which affects the area behind the nose and throat. The goal is to see how effective this imaging method is for patients whose cancer is at a locally advanced stage, meaning it has spread to nearby areas but not to distant parts of the body.

To participate in this study, patients need to be diagnosed with a specific type of nasopharyngeal carcinoma and meet certain health criteria, such as having a good performance status (meaning they can carry out daily activities). They must be between the ages of 18 and 70 and should not have had previous cancer treatments, significant other health issues, or conditions like severe heart disease. Participants will undergo imaging tests and will be closely monitored throughout the trial. If you or a loved one are interested in this study, it’s important to discuss it with your healthcare provider to see if you qualify and to understand what it involves.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly histologically confirmed non-keratinizing carcinoma.
• • Tumor staged T1-4N0-3M0 （according to the 8th AJCC staging system）
• • Performance status: KPS\>70
• • With normal liver function test (ALT, AST \<1.5ULN)
• • Renal: creatinine clearance \>60ml/min
• • Without hematopathy,marrow: WBC \>4\*109/L, HGB\>80G/L, and PLT\>100\*109/L.
• • Written informed consent
• Exclusion Criteria:
• • Adenocarcinoma
• • Age \>70
• • Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin)
• • Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)
• • Patient is pregnant or lactating
• • Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.